Largeron N - Search Results

1

Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.

Gervais F, Dunton K, Jiang Y, Largeron N. Gervais F, et al. Among authors: largeron n. BMC Public Health. 2017 Mar 28;17(1):283. doi: 10.1186/s12889-017-4076-3. BMC Public Health. 2017. PMID: 28351348 Free PMC article. Review.

2

A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus.

Jiang Y, Gauthier A, Postma MJ, Ribassin-Majed L, Largeron N, Bresse X. Jiang Y, et al. Among authors: largeron n. Hum Vaccin Immunother. 2013 Nov;9(11):2285-95. doi: 10.4161/hv.25754. Epub 2013 Jul 23. Hum Vaccin Immunother. 2013. PMID: 23880955 Free PMC article. Review.

3

Critical Review of Cost-Effectiveness Analyses (CEA) of Prevention Strategies Against Diseases Associated with Human Papillomavirus (HPV) Infection.

Gervais F, Jiang Y, Largeron N, Nikoglou T. Gervais F, et al. Among authors: largeron n. Value Health. 2014 Nov;17(7):A637. doi: 10.1016/j.jval.2014.08.2288. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202273 Free article. No abstract available.

4

Discounting role in cost-effectiveness of HPV vaccination by Starkie Camejo et al. (Public Health Vol 129(7):989-92).

Butt T, Drury R, Largeron N. Butt T, et al. Among authors: largeron n. Public Health. 2016 Mar;132:108-9. doi: 10.1016/j.puhe.2015.10.038. Epub 2015 Dec 22. Public Health. 2016. PMID: 26725592 No abstract available.

5

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.

Boiron L, Joura E, Largeron N, Prager B, Uhart M. Boiron L, et al. Among authors: largeron n. BMC Infect Dis. 2016 Apr 16;16:153. doi: 10.1186/s12879-016-1483-5. BMC Infect Dis. 2016. PMID: 27084683 Free PMC article.

6

Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model.

Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ; Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group). Rozenbaum MH, et al. BMC Public Health. 2011 Jun 10;11:462. doi: 10.1186/1471-2458-11-462. BMC Public Health. 2011. PMID: 21663620 Free PMC article.

7

Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review.

Préaud E, Largeron N. Préaud E, et al. Among authors: largeron n. J Med Econ. 2013;16(6):763-76. doi: 10.3111/13696998.2013.793691. Epub 2013 Apr 24. J Med Econ. 2013. PMID: 23565814 Free article. Review.

8

Mind the gaps: what's missing from current economic evaluations of universal HPV vaccination?

Marsh K, Chapman R, Baggaley RF, Largeron N, Bresse X. Marsh K, et al. Among authors: largeron n. Vaccine. 2014 Jun 24;32(30):3732-9. doi: 10.1016/j.vaccine.2014.05.007. Epub 2014 May 15. Vaccine. 2014. PMID: 24837538 Review.

9

An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany.

Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. Largeron N, et al. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):85-98. doi: 10.1080/14737167.2016.1208087. Epub 2016 Jul 15. Expert Rev Pharmacoecon Outcomes Res. 2017. PMID: 27366939

10

A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.

Bresse X, Adam M, Largeron N, Roze S, Marty R. Bresse X, et al. Among authors: largeron n. Hum Vaccin Immunother. 2013 Apr;9(4):823-33. doi: 10.4161/hv.22994. Epub 2013 Apr 1. Hum Vaccin Immunother. 2013. PMID: 23563511 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters